Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) said the 400 million yuan venture capital fund it invested in completed its industrial and commercial registration, according to a Shanghai Stock Exchange disclosure on Tuesday.
The fund, Guangzhou Guangyao Industrial Investment Venture Capital Fund Partnership (Limited Partnership), completed the filing procedures with the Asset Management Association of China, the pharmaceutical company said.
Baiyunshan Pharma's Shanghai shares slipped more than 1% and Hong Kong shares fell less than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.